Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$211.80-0.8%$189.84$153.58▼$218.66$373.91B0.616.16 million shs6.14 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.89%+0.09%+11.30%+22.32%+17.10%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.6644 of 5 stars2.45.03.33.93.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$211.45-0.17% DownsideCurrent Analyst Ratings BreakdownLatest ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.003/4/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.002/3/2025ABBVAbbVieCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$205.00 ➝ $215.002/3/2025ABBVAbbVieTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $217.002/3/2025ABBVAbbVieUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$181.00 ➝ $190.002/3/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$195.00 ➝ $210.002/3/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$224.00 ➝ $239.002/3/2025ABBVAbbVieRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$218.00 ➝ $220.002/3/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$212.00 ➝ $214.002/3/2025ABBVAbbVieBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$208.00 ➝ $215.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.64$15.65 per share13.53$1.90 per share111.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.4088.2515.151.627.59%296.28%12.65%4/25/2025 (Estimated)Latest ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails1/31/2025Q4 24ABBVAbbVie$2.98$2.16-$0.82-$0.02$14.81 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.10%+6.04%273.33%53 YearsLatest ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/14/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableABBV HeadlinesRecent News About These CompaniesAbbVie regained TV ad spending lead amid February slowdown, with Rinvoq and Skyrizi back on topMarch 12 at 5:00 PM | fiercepharma.comAbbVie (NYSE:ABBV) Shares Down 0.8% - Time to Sell?March 12 at 3:32 PM | marketbeat.comWhy AbbVie Inc. (ABBV) is the Best Pharma Stock to Buy According to Hedge FundsMarch 12 at 2:57 PM | insidermonkey.comBest Biotech Stocks To Watch Now - March 12thMarch 12 at 2:11 PM | marketbeat.comAbbVie price target raised to $195 from $165 at BerenbergMarch 12 at 11:59 AM | markets.businessinsider.comAbbVie Inc. (NYSE:ABBV) Shares Sold by Avantax Advisory Services Inc.March 12 at 7:51 AM | marketbeat.comJupiter Asset Management Ltd. Acquires Shares of 276,669 AbbVie Inc. (NYSE:ABBV)March 12 at 7:40 AM | marketbeat.comSecurian Asset Management Inc. Sells 2,718 Shares of AbbVie Inc. (NYSE:ABBV)March 12 at 7:34 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Position Lifted by Great Lakes Advisors LLCMarch 12 at 7:22 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Sold by Westchester Capital Management Inc.March 12 at 7:21 AM | marketbeat.comTruvestments Capital LLC Boosts Holdings in AbbVie Inc. (NYSE:ABBV)March 12 at 7:20 AM | marketbeat.comCapasso Planning Partners LLC Sells 2,598 Shares of AbbVie Inc. (NYSE:ABBV)March 12 at 7:11 AM | marketbeat.com2,016 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Hopwood Financial Services Inc.March 12 at 7:10 AM | marketbeat.comWorried About a Market Meltdown? 2 Dividend Stocks to Own Forever.March 12 at 7:10 AM | fool.comPFG Advisors Has $3.98 Million Holdings in AbbVie Inc. (NYSE:ABBV)March 12 at 6:30 AM | marketbeat.comHighTower Advisors LLC Buys 100,418 Shares of AbbVie Inc. (NYSE:ABBV)March 12 at 6:22 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) is Windle Wealth LLC's 10th Largest PositionMarch 12 at 6:14 AM | marketbeat.comAbbVie Inc. (NYSE:ABBV) Shares Sold by River Road Asset Management LLCMarch 12 at 5:21 AM | marketbeat.comPzena Investment Management LLC Takes Position in AbbVie Inc. (NYSE:ABBV)March 12 at 5:20 AM | marketbeat.comWith AbbVie in its sights, Tenpoint names commercial chief ahead of vision drug launchMarch 12 at 1:34 AM | fiercepharma.comAbbVie's Rob Michael collected $18.5M in '24 CEO debutMarch 12 at 1:34 AM | fiercepharma.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABBV Company DescriptionsAbbVie NYSE:ABBV$211.80 -1.79 (-0.84%) Closing price 03/12/2025 03:58 PM EasternExtended Trading$211.89 +0.09 (+0.04%) As of 03/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
